Institutional members access full text with Ovid®

Share this article on:

Prenatal cfDNA Screening Results Indicative of Maternal Neoplasm: Survey of Current Practice and Management Needs

Giles, Meagan E.; Murphy, Lauren; Krstić, Nevena; Sullivan, Cathy; Hashmi, Syed S.; Stevens, Blair

Obstetrical & Gynecological Survey: April 2017 - Volume 72 - Issue 4 - p 214–215
doi: 10.1097/01.ogx.0000515493.54328.24
Obstetrics: Genetics

(Abstracted from Prenat Diagn 2017;37(2):126–132)

The discovery of cell-free fetal DNA (cfDNA) that is free-floating in the serum has led to the development of screening technologies, both in obstetrics and oncology. Circulating cfDNA in the serum of pregnant women is the basis of noninvasive prenatal testing (NIPT).

Genetic Counseling Program, University of Texas Graduate School of Biomedical Sciences at Houston (M.E.G., L.M., N.K., B.S.); Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School (L.M., N.K., B.S.); Lester and Sue Breast Center, Baylor College of Medicine (C.S.); and Department of Pediatrics, McGovern Medical School (S.S.H.), Houston, TX

Topics: obstetrics, oncology, cell-free DNA.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.